MPM BioVentures 2018 GP LLC 4

Accession 0000899243-20-020691

CIK 0001808865other

View on SEC.gov Company Profile

Filed

Jul 28, 8:00 PM ET

Accepted

Jul 29, 9:45 PM ET

Size

81.2 KB

Accession

0000899243-20-020691

Insider Transaction Report

Form 4

Period: 2020-07-28

iTeos Therapeutics, Inc.ITOS

MPM BioVentures 2014, L.P.

Other

Transactions

Conversion
Common Stock
2020-07-28+42,605→ 42,605 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+24,944→ 68,381 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+24,326→ 66,931 total(indirect: See Footnote)
Conversion
Series B Preferred Stock
2020-07-28−2,415,530→ 0 total(indirect: See Footnote)
→ Common Stock (801,619 underlying)
Conversion
Series B Preferred Stock
2020-07-28−128,384→ 0 total(indirect: See Footnote)
→ Common Stock (42,605 underlying)
Conversion
Series B-2 Preferred Stock
2020-07-28−157,529→ 0 total(indirect: See Footnote)
→ Common Stock (48,336 underlying)
Conversion
Series B-2 Preferred Stock
2020-07-28−1,491,666→ 0 total(indirect: See Footnote)
→ Common Stock (457,706 underlying)
Purchase
Common Stock
2020-07-28$19.00/sh+1,121$21,299→ 25,974 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+84,655→ 84,655 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+801,619→ 801,619 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+15,820→ 15,820 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+9,033→ 24,853 total(indirect: See Footnote)
Purchase
Common Stock
2020-07-28$19.00/sh+56,814$1,079,466→ 1,316,139 total(indirect: See Footnote)
Conversion
Series B-2 Preferred Stock
2020-07-28−2,361,805→ 0 total(indirect: See Footnote)
→ Common Stock (724,702 underlying)
Conversion
Series B-2 Preferred Stock
2020-07-28−81,295→ 0 total(indirect: See Footnote)
→ Common Stock (24,944 underlying)
Conversion
Series B-2 Preferred Stock
2020-07-28−79,281→ 0 total(indirect: See Footnote)
→ Common Stock (24,326 underlying)
Conversion
Common Stock
2020-07-28+1,269,230→ 1,269,230 total(indirect: See Footnote)
Conversion
Series B Preferred Stock
2020-07-28−131,645→ 0 total(indirect: See Footnote)
→ Common Stock (43,687 underlying)
Conversion
Series B Preferred Stock
2020-07-28−47,674→ 0 total(indirect: See Footnote)
→ Common Stock (15,820 underlying)
Purchase
Common Stock
2020-07-28$19.00/sh+3,096$58,824→ 71,727 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+43,687→ 43,687 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+724,702→ 1,993,932 total(indirect: See Footnote)
Purchase
Common Stock
2020-07-28$19.00/sh+89,955$1,709,145→ 2,083,887 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+48,336→ 132,991 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+457,706→ 1,259,325 total(indirect: See Footnote)
Purchase
Common Stock
2020-07-28$19.00/sh+5,994$113,886→ 138,985 total(indirect: See Footnote)
Purchase
Common Stock
2020-07-28$19.00/sh+3,020$57,380→ 69,951 total(indirect: See Footnote)
Conversion
Series B Preferred Stock
2020-07-28−3,824,591→ 0 total(indirect: See Footnote)
→ Common Stock (1,269,230 underlying)
Conversion
Series B Preferred Stock
2020-07-28−255,094→ 0 total(indirect: See Footnote)
→ Common Stock (84,655 underlying)
Conversion
Series B-2 Preferred Stock
2020-07-28−29,440→ 0 total(indirect: See Footnote)
→ Common Stock (9,033 underlying)

MPM BioVentures 2018 LLC

Other

Transactions

Conversion
Common Stock
2020-07-28+43,687→ 43,687 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+42,605→ 42,605 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+15,820→ 15,820 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+457,706→ 1,259,325 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+9,033→ 24,853 total(indirect: See Footnote)
Purchase
Common Stock
2020-07-28$19.00/sh+5,994$113,886→ 138,985 total(indirect: See Footnote)
Purchase
Common Stock
2020-07-28$19.00/sh+3,096$58,824→ 71,727 total(indirect: See Footnote)
Purchase
Common Stock
2020-07-28$19.00/sh+1,121$21,299→ 25,974 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+1,269,230→ 1,269,230 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+84,655→ 84,655 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+801,619→ 801,619 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+48,336→ 132,991 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+24,944→ 68,381 total(indirect: See Footnote)
Conversion
Series B Preferred Stock
2020-07-28−47,674→ 0 total(indirect: See Footnote)
→ Common Stock (15,820 underlying)
Conversion
Series B-2 Preferred Stock
2020-07-28−2,361,805→ 0 total(indirect: See Footnote)
→ Common Stock (724,702 underlying)
Conversion
Common Stock
2020-07-28+24,326→ 66,931 total(indirect: See Footnote)
Purchase
Common Stock
2020-07-28$19.00/sh+56,814$1,079,466→ 1,316,139 total(indirect: See Footnote)
Purchase
Common Stock
2020-07-28$19.00/sh+3,020$57,380→ 69,951 total(indirect: See Footnote)
Conversion
Series B Preferred Stock
2020-07-28−3,824,591→ 0 total(indirect: See Footnote)
→ Common Stock (1,269,230 underlying)
Conversion
Series B-2 Preferred Stock
2020-07-28−81,295→ 0 total(indirect: See Footnote)
→ Common Stock (24,944 underlying)
Conversion
Series B-2 Preferred Stock
2020-07-28−79,281→ 0 total(indirect: See Footnote)
→ Common Stock (24,326 underlying)
Conversion
Series B Preferred Stock
2020-07-28−255,094→ 0 total(indirect: See Footnote)
→ Common Stock (84,655 underlying)
Conversion
Series B Preferred Stock
2020-07-28−2,415,530→ 0 total(indirect: See Footnote)
→ Common Stock (801,619 underlying)
Conversion
Series B-2 Preferred Stock
2020-07-28−157,529→ 0 total(indirect: See Footnote)
→ Common Stock (48,336 underlying)
Conversion
Series B-2 Preferred Stock
2020-07-28−1,491,666→ 0 total(indirect: See Footnote)
→ Common Stock (457,706 underlying)
Conversion
Common Stock
2020-07-28+724,702→ 1,993,932 total(indirect: See Footnote)
Purchase
Common Stock
2020-07-28$19.00/sh+89,955$1,709,145→ 2,083,887 total(indirect: See Footnote)
Conversion
Series B Preferred Stock
2020-07-28−131,645→ 0 total(indirect: See Footnote)
→ Common Stock (43,687 underlying)
Conversion
Series B Preferred Stock
2020-07-28−128,384→ 0 total(indirect: See Footnote)
→ Common Stock (42,605 underlying)
Conversion
Series B-2 Preferred Stock
2020-07-28−29,440→ 0 total(indirect: See Footnote)
→ Common Stock (9,033 underlying)

MPM BioVentures 2018 GP LLC

Other

Transactions

Conversion
Common Stock
2020-07-28+24,326→ 66,931 total(indirect: See Footnote)
Purchase
Common Stock
2020-07-28$19.00/sh+5,994$113,886→ 138,985 total(indirect: See Footnote)
Conversion
Series B-2 Preferred Stock
2020-07-28−81,295→ 0 total(indirect: See Footnote)
→ Common Stock (24,944 underlying)
Conversion
Common Stock
2020-07-28+84,655→ 84,655 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+801,619→ 801,619 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+15,820→ 15,820 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+724,702→ 1,993,932 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+48,336→ 132,991 total(indirect: See Footnote)
Purchase
Common Stock
2020-07-28$19.00/sh+89,955$1,709,145→ 2,083,887 total(indirect: See Footnote)
Purchase
Common Stock
2020-07-28$19.00/sh+3,096$58,824→ 71,727 total(indirect: See Footnote)
Purchase
Common Stock
2020-07-28$19.00/sh+56,814$1,079,466→ 1,316,139 total(indirect: See Footnote)
Purchase
Common Stock
2020-07-28$19.00/sh+1,121$21,299→ 25,974 total(indirect: See Footnote)
Conversion
Series B Preferred Stock
2020-07-28−255,094→ 0 total(indirect: See Footnote)
→ Common Stock (84,655 underlying)
Conversion
Series B Preferred Stock
2020-07-28−131,645→ 0 total(indirect: See Footnote)
→ Common Stock (43,687 underlying)
Conversion
Series B Preferred Stock
2020-07-28−2,415,530→ 0 total(indirect: See Footnote)
→ Common Stock (801,619 underlying)
Conversion
Series B Preferred Stock
2020-07-28−128,384→ 0 total(indirect: See Footnote)
→ Common Stock (42,605 underlying)
Conversion
Series B-2 Preferred Stock
2020-07-28−157,529→ 0 total(indirect: See Footnote)
→ Common Stock (48,336 underlying)
Conversion
Series B-2 Preferred Stock
2020-07-28−79,281→ 0 total(indirect: See Footnote)
→ Common Stock (24,326 underlying)
Conversion
Common Stock
2020-07-28+457,706→ 1,259,325 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+9,033→ 24,853 total(indirect: See Footnote)
Conversion
Series B Preferred Stock
2020-07-28−3,824,591→ 0 total(indirect: See Footnote)
→ Common Stock (1,269,230 underlying)
Conversion
Series B-2 Preferred Stock
2020-07-28−2,361,805→ 0 total(indirect: See Footnote)
→ Common Stock (724,702 underlying)
Conversion
Series B-2 Preferred Stock
2020-07-28−1,491,666→ 0 total(indirect: See Footnote)
→ Common Stock (457,706 underlying)
Conversion
Series B-2 Preferred Stock
2020-07-28−29,440→ 0 total(indirect: See Footnote)
→ Common Stock (9,033 underlying)
Conversion
Common Stock
2020-07-28+43,687→ 43,687 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+42,605→ 42,605 total(indirect: See Footnote)
Conversion
Common Stock
2020-07-28+24,944→ 68,381 total(indirect: See Footnote)
Purchase
Common Stock
2020-07-28$19.00/sh+3,020$57,380→ 69,951 total(indirect: See Footnote)
Conversion
Series B Preferred Stock
2020-07-28−47,674→ 0 total(indirect: See Footnote)
→ Common Stock (15,820 underlying)
Conversion
Common Stock
2020-07-28+1,269,230→ 1,269,230 total(indirect: See Footnote)

Footnotes (13)

[F1]Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
[F10]On July 28, 2020, MPM Asset Management Investors BV 2014 LLC purchased 3,096 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
[F11]On July 28, 2020, BV 2018 purchased 56,814 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
[F12]On July 28, 2020, BV 2018(B) purchased 3,020 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
[F13]On July 28, 2020, MPM Asset Management Investors BV 2018 LLC purchased 1,121 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
[F2]The shares of Series B Convertible Preferred stock held by MPM BioVentures 2014 LP ("BV 2014") will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM BioVentures 2014 (B) LP ("BV 2014(B)") will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM BioVentures 2018 LP ("BV 2018") will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering.
[F3](Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM BioVentures 2018 (B) LP ("BV 2018(B)") will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2014 will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2014(B) will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering.
[F4](Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2018 will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2018(B) will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020.
[F5]MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("2014 BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). Luke Evnin, Ansbert Gadicke and Todd Foley are the managing directors of 2014 BV LLC and members of MPM Asset Management Investors BV2014 LLC.
[F6]MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("2018 BV LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). Luke Evnin, Ansbert Gadicke, Todd Foley and Edward Hurwitz are the managing directors of 2018 BV LLC and members of MPM Asset Management Investors BV2018 LLC.
[F7]Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
[F8]On July 28, 2020, BV 2014 purchased 89,955 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
[F9]On July 28, 2020, BV 2014(B) purchased 5,994 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

iTeos Therapeutics, Inc.

CIK 0001808865

→

Entity typeother

IncorporatedDE

Related Parties

filerCIK 0001818701

Filing Metadata

Form type: 4
Filed: Jul 28, 8:00 PM ET
Accepted: Jul 29, 9:45 PM ET
Size: 81.2 KB

View on SEC.gov